Quick Answer
Lineage Cell Therapeutics, Inc. reported Operating Income Loss of -$36.62 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -70.5% in Operating Income Loss from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Lineage Cell Therapeutics, Inc.'s Operating Income Loss has declined by 940.2%.
- Historical annual values: Fiscal year 2025: -$36.62 million | Fiscal year 2024: -$21.48 million | Fiscal year 2023: -$24.73 million | Fiscal year 2022: -$22.52 million | Fiscal year 2021: -$49.21 million | Fiscal year 2020: -$26.45 million | Fiscal year 2019: -$38.88 million | Fiscal year 2018: -$41.80 million | Fiscal year 2017: -$38.90 million | Fiscal year 2016: -$58.97 million | Fiscal year 2015: -$65.81 million | Fiscal year 2014: -$50.68 million | Fiscal year 2013: -$55.99 million | Fiscal year 2012: -$25.00 million | Fiscal year 2011: -$18.69 million | Fiscal year 2010: -$9.85 million | Fiscal year 2009: -$3.52 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: